Rather than providing protection, an Omicron infection may leave patients more susceptible to future COVID infections, researchers find after studying seniors in care

Researchers at McMaster University have found that rather than conferring immunity against future infections, infection during the first Omicron wave of COVID left the seniors they studied much more vulnerable to reinfection during the second Omicron wave.

Novel Research Sheds Light on Antibody Responses to the SARS-CoV-2 Virus and Vaccines

Two studies presented today at the 2022 AACC Annual Scientific Meeting & Clinical Lab Expo reveal how SARS-CoV-2 antibody levels vary among recipients of COVID-19 vaccines and naturally infected individuals. These findings add to a growing body of knowledge that is essential for guiding public health initiatives, and that might one day enable clinicians to assess individuals’ immunity to SARS-CoV-2.

New Research at the 2021 AACC Annual Scientific Meeting Captures SARS-CoV-2 Antibody Patterns in Vaccinated and Naturally Infected Individuals

Two new studies presented today at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo reveal how antibodies against the SARS-CoV-2 virus can vary among recipients of different COVID-19 vaccines and naturally infected individuals. The findings provide critical data about the immune response to COVID-19 vaccines that could inform future diagnostic research and vaccination efforts.

New Johns Hopkins Center for Research on COVID-19 Immunity

Researchers at the Johns Hopkins Bloomberg School of Public Health and Johns Hopkins University School of Medicine have been jointly awarded a major grant from the National Cancer Institute, part of the National Institutes of Health, to set up a center for research on the human serological immune response to SARS-CoV-2, the coronavirus that causes COVID-19.

New York State Department of Health Grants Emergency Use Authorization to Mount Sinai for Quantitative COVID-19 Antibody Test

The Clinical Laboratories of The Mount Sinai Hospital has received emergency use authorization from the New York State Department of Health (NYSDOH) for quantitative use of Mount Sinai’s COVID-19 antibody test, making Mount Sinai’s lab the first in the country to run an authorized, fully quantitative antibody test that can deliver a precise numeric measurement of the level of antibodies in a patient’s blood